In both myeloid and lymphoid leukaemia cell lines, all combination treatments caused a synergistic increase in CASP-9 and CASP-3 gene expression when compared to the vehicle control and drugs alone (P ≤ 0.05) (Fig. 7A). The gene discussed is CASP9; the disease is lymphoid leukemia.